CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...